Literature DB >> 21341373

Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.

Mariangela Biava1, Giulio Cesare Porretta, Giovanna Poce, Claudio Battilocchio, Salvatore Alfonso, Alessandro de Logu, Fabrizio Manetti, Maurizio Botta.   

Abstract

Tuberculosis (TB) represents a never-ending challenge toward which research efforts are needed. Drug resistance is the key problem that scientists in the field need to fight. The development of new drugs endowed with novel modes of action against different biological targets is of extreme importance; these new agents should also exhibit lower toxicity compared with the anti-TB drugs currently available. Furthermore, new drugs should be inexpensive since most of the TB-infected population lives in developing nations. In the last few years, numerous researchers have focused their attention on TB, leading to the discovery of some interesting compounds. Among these, the pyrrole-derived compounds we developed can be considered very promising antimycobacterial agents. Aided by molecular modeling studies, we synthesized numerous compounds characterized by the same 1,5-diarylpyrrole scaffold and elucidated very interesting antitubercular/antimycobacterial properties. Some compounds identified are extremely promising and represent a step towards the design of novel lead structures in the fight against TB. Our efforts to this end are reviewed here.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21341373     DOI: 10.1002/cmdc.201000526

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  4 in total

1.  Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Authors:  Giovanna Poce; Sara Consalvi; Giulia Venditti; Salvatore Alfonso; Nicoletta Desideri; Raquel Fernandez-Menendez; Robert H Bates; Lluis Ballell; David Barros Aguirre; Joaquin Rullas; Alessandro De Logu; Michelle Gardner; Thomas R Ioerger; Eric J Rubin; Mariangela Biava
Journal:  ACS Med Chem Lett       Date:  2019-09-18       Impact factor: 4.345

2.  MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.

Authors:  Valentina La Rosa; Giovanna Poce; Julio Ortiz Canseco; Silvia Buroni; Maria Rosalia Pasca; Mariangela Biava; Ravikiran M Raju; Giulio Cesare Porretta; Salvatore Alfonso; Claudio Battilocchio; Babak Javid; Flavia Sorrentino; Thomas R Ioerger; James C Sacchettini; Fabrizio Manetti; Maurizio Botta; Alessandro De Logu; Eric J Rubin; Edda De Rossi
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

Review 3.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

4.  Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.

Authors:  Giovanna Poce; Robert H Bates; Salvatore Alfonso; Martina Cocozza; Giulio Cesare Porretta; Lluís Ballell; Joaquin Rullas; Fátima Ortega; Alessandro De Logu; Emanuela Agus; Valentina La Rosa; Maria Rosalia Pasca; Edda De Rossi; Baojie Wae; Scott G Franzblau; Fabrizio Manetti; Maurizio Botta; Mariangela Biava
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.